 The patient with severe eye involvement in mucus membrane pemphagoid, MMP, successfully treated for COVID-19 using high-dose intravenous immunoglobulin, IVIG, antiviral treatment including hydroxychloroquine, lopinavia, rightonavir and ribovirin, had finished a 2G cycle of rituximab, RTX, in late January, was on mycophenolate moftill, MMF, for one month and prednisolone for three months until his hospitalisation, and tapered prednisolone to 15mg when current COVID-19 was suspected. This article was authored by Miriam Danish-Pazhoo, Tahira Soori, RDI Cizade, and others.